SLC3A2 and osteosarcoma: Targeting SLC3A2 efficiently decreases colony formation of osteosarcoma cells10 and affects renal cancer cell growth in vivo.35 The consequences of blocking SLC3A2 is therefore warranted in the aggressive highly proliferative BC subtypes.